ClinicalTrials.gg
CompletedNCT02118714Updated May 7, 2019Results posted

Atrasentan Spermatogenesis and Testicular Function

A Phase 2 interventional study of Atrasentan in Nephropathy and Diabetes, sponsored by AbbVie. Completed at 13 sites in 4 countries. Open to male participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-05-07.

Sponsored by AbbVie · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
30 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 416 studies in Kidney Diseases with a site in United States — 64 open to participants now, 93 under way, 15 of them phase 3. Kidney Diseases · United States.

Enrollment
237th of 318
20 · median 50
Started
2015
with 17 others
Phase 2
67 of 416
6 open now
Registered
188th of 416
by date

Among the 416 studies in Kidney Diseases with a site in United States, this one is the 237th largest by enrollment of the 318 interventional ones that give a count, is one of 18 that started in 2015, is one of 67 in phase 2, and was the 188th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

64 of the 416 studies in Kidney Diseases with a site in United States are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.

This study: 30 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 416 studies in Kidney Diseases with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the effects of Atrasentan on sperm production and testicular function in male subjects with Type 1 or 2 Diabetes and Nephropathy.

This study included 2 periods: a Treatment Period (up to 26 weeks) followed by an Observational Period (up to an additional 52 weeks).

03

Conditions studied

  • Nephropathy
  • Diabetes

Keywords

  • Diabetic Nephropathies
  • Kidney Diseases
  • Urologic Diseases
  • Diabetes Complications
  • Diabetes Mellitus
  • Endocrine System Diseases
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males 30 to 75 years of age
  • Type 1 or 2 diabetes and receiving treatment with at least one anti-hyperglycemic medication and angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) (renin-angiotensin system [RAS] inhibitor)
  • Estimated (eGFR) equal to or greater than 35 mL/min/1.73 m\^2 with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula and Urine Albumin-to-Creatinine Ratio (UACR) equal to or greater than 30 and less than 5,000 mg/g creatinine.
  • Able to provide a semen specimen at the required intervals.
  • Baseline sperm concentration equal to or greater than 30 million per mL.

Exclusion criteria

Exclusion Criteria:

  • Treatment with hormone suppressive agents or cancer chemotherapy within the 6 months prior to the initial screening visit or planned during the study.
  • History of severe peripheral edema or facial edema unrelated to trauma or history of myxedema in the prior 4 weeks prior to screening.
  • History of pulmonary hypertension, pulmonary fibrosis or any lung disease requiring oxygen therapy.
  • Documented diagnosis of heart failure, previous hospitalization for heart failure or current or constellation of symptoms (dyspnea on exertion, pedal edema, orthopnea, paroxysmal nocturnal dyspnea) felt to be compatible with heart failure, that was not explained by other causes, and for which there was a change in medication or other management directed at heart failure.
  • Currently receiving or has received hormone replacement therapy within 6 months prior to screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Atrasentan

    Atrasentan 0.75 mg administered orally once daily (QD) for 26 weeks

    Drug: Atrasentan

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26

    Percentage of Subjects with a Sperm Concentration \< 15 million per mL by Treatment Week 26. Sperm concentration was calculated as measure of the number sperm per milliliter of semen. Duplicate semen samples were collected. The average of the 2 samples were used as the value for that scheduled collection period.

    Time frame: Up to 26 weeks

Secondary outcomes

  1. Percentage of Participants Who Entered the Observation Period and Did Not Return to Within 15% of Baseline Sperm Concentration or Above During the 52-Week Observational Period

    The percentage of participants who entered the Observational Period and did not return to within 15% of Baseline sperm concentration or above during the 52-week Observational Period. Duplicate semen samples were to be collected during the Observational Period. Sperm concentration was calculated as measure of the number sperm per milliliter of semen. Duplicate semen samples were collected. The average of the 2 samples were used as the value for that scheduled collection period.

    Time frame: Up to 52 weeks after the Treatment Period

  2. Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration

    Duplicate semen samples will be collected during the Treatment and Observational Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a decrease in sperm concentration.

    Time frame: From Week 0 up to Treatment Period Week 26 and Observation Period Week 52

  3. Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility

    Duplicate semen samples will be collected during the Treatment and Observation Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a lower sperm motility (worsening).

    Time frame: From Week 0 up to Treatment Period Week 26 and Observation Observation Week 52

  4. Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology

    Duplicate semen samples will be collected during the Treatment and Observational Periods. The percentage of sperm with normal versus abnormal morphology will be determined via microscopic analysis. A positive change from baseline indicates an improved sperm morphology.

    Time frame: From Week 0 up to Treatment Period Week 26 and Observation Period Week 52

  5. Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Semen Volume

    Duplicate semen samples will be collected during the Treatment and Observation Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a decrease in semen volume.

    Time frame: From Week 0 to up to Treatment Period Week 26 and Observation Period Week 52

  6. Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Serum Testosterone

    Serum hormones levels will be tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum testosterone.

    Time frame: From Week 0 up to Treatment Period Week 26 and Observation Period Week 52

  7. Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Estradiol

    Serum hormones levels were tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum estradiol.

    Time frame: From Week 0 up to Treatment Period Week 26 and Observation Period Week 52

  8. Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Lutenizing Hormone (LH)

    Serum hormones levels will be tested during the Treatment and Observational Periods. A positive change from baseline indicated an increase in serum lutenizing hormone.

    Time frame: From Week 0 to up to Treatment Period Week 26 and Observation Period Week 52

  9. Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in in Follicle Stimulating Hormone (FSH)

    Serum hormones levels will be tested during the Treatment and Observational Periods. A positive change from baseline indicated an increase in serum follicle stimulating hormone.

    Time frame: From Week 0 to Treatment Week 26 and Observation Week 52

  10. Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Inhibin B

    Serum hormones levels will be tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum Inhibin B.

    Time frame: From Week 0 up to Treatment Period Week 26 and Observation Period Week 52

07

Results

Posted May 7, 2019

Participant flow

Participant flow — Overall Study
MilestoneAtrasentan
Started20
Completed17
Not completed3
Withdrew: Lost to follow-up2
Withdrew: Protocol violation1

Outcome measures

PrimaryPercentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26

Percentage of Subjects with a Sperm Concentration \< 15 million per mL by Treatment Week 26. Sperm concentration was calculated as measure of the number sperm per milliliter of semen. Duplicate semen samples were collected. The average of the 2 samples were used as the value for that scheduled collection period.

Time frame:
Up to 26 weeks
Reported as:
Number · percentage of participants
Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26
percentage of participantsAtrasentan
Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 2623.5
Statistical analysis
  • Atrasentan · Percentage of participants: 23.5 · 80% CI 10.7 to 41.6
  • Atrasentan · Percentage of participants: 23.5 · 95% CI 6.8 to 49.9
SecondaryPercentage of Participants Who Entered the Observation Period and Did Not Return to Within 15% of Baseline Sperm Concentration or Above During the 52-Week Observational Period

The percentage of participants who entered the Observational Period and did not return to within 15% of Baseline sperm concentration or above during the 52-week Observational Period. Duplicate semen samples were to be collected during the Observational Period. Sperm concentration was calculated as measure of the number sperm per milliliter of semen. Duplicate semen samples were collected. The average of the 2 samples were used as the value for that scheduled collection period.

Time frame:
Up to 52 weeks after the Treatment Period
Reported as:
Number · percentage of participants
Percentage of Participants Who Entered the Observation Period and Did Not Return to Within 15% of Baseline Sperm Concentration or Above During the 52-Week Observational Period
percentage of participantsAtrasentan
Percentage of Participants Who Entered the Observation Period and Did Not Return to Within 15% of Baseline Sperm Concentration or Above During the 52-Week Observational Period11.8
Statistical analysis
  • Atrasentan · Percentage of participants: 11.8 · 80% CI 3.2 to 28.4
  • Atrasentan · Percentage of participants: 11.8 · 95% CI 1.5 to 36.4
SecondaryChange From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration

Duplicate semen samples will be collected during the Treatment and Observational Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a decrease in sperm concentration.

Time frame:
From Week 0 up to Treatment Period Week 26 and Observation Period Week 52
Reported as:
Mean · sperm * million per milliliter(X10^6/mL)
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration
sperm * million per milliliter(X10^6/mL)Atrasentan
Treatment Period Week 132.2 ± 42.21
Treatment Period Week 26-10.6 ± 53.44
Observation Period Week 1335.8 ± 113.60
Observation Period Week 26-16.5 ± 0.00
Observation Period Week 39-27.5 ± 19.09
Observation Period Week 52-25.8 ± 1.06
SecondaryChange From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility

Duplicate semen samples will be collected during the Treatment and Observation Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a lower sperm motility (worsening).

Time frame:
From Week 0 up to Treatment Period Week 26 and Observation Observation Week 52
Reported as:
Mean · percent motility
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility
percent motilityAtrasentan
Treatment Period Week 13-5.8 ± 13.65
Treatment Period Week 26-7.4 ± 15.77
Observation Period Week 13-0.3 ± 19.20
Observation Period Week 26-6.3 ± 5.30
Observation Period Week 3910.8 ± 15.20
Observation Period Week 521.8 ± 16.62
SecondaryChange From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology

Duplicate semen samples will be collected during the Treatment and Observational Periods. The percentage of sperm with normal versus abnormal morphology will be determined via microscopic analysis. A positive change from baseline indicates an improved sperm morphology.

Time frame:
From Week 0 up to Treatment Period Week 26 and Observation Period Week 52
Reported as:
Mean · percentage of normal
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology
percentage of normalAtrasentan
Treatment Period Week 13-1.1 ± 4.78
Treatment Period Week 26-2.2 ± 7.54
Observation Period Week 13-0.8 ± 7.53
Observation Period Week 26-6.8 ± 0.35
Observation Period Week 39-2.3 ± 1.77
Observation Period Week 521.8 ± 0.35
SecondaryChange From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Semen Volume

Duplicate semen samples will be collected during the Treatment and Observation Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a decrease in semen volume.

Time frame:
From Week 0 to up to Treatment Period Week 26 and Observation Period Week 52
Reported as:
Mean · milliliter (mL)
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Semen Volume
milliliter (mL)Atrasentan
Treatment Period Week 130.0 ± 0.65
Treatment Period Week 26-0.3 ± 0.75
Observation Period Week 130.0 ± 1.39
Observation Period Week 260.0 ± 0.35
Observation Period Week 390.1 ± 0.42
Observation Period Week 52-0.4 ± 0.14
SecondaryChange From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Serum Testosterone

Serum hormones levels will be tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum testosterone.

Time frame:
From Week 0 up to Treatment Period Week 26 and Observation Period Week 52
Reported as:
Mean · nanomole/liter (nmol/L)
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Serum Testosterone
nanomole/liter (nmol/L)Atrasentan
Treatment Period Week 130.2 ± 2.18
Treatment Period Week 260.8 ± 2.33
Observation Period Week 130.6 ± 2.08
Observation Period Week 26-0.3 ± 0.85
Observation Period Week 39-1.6 ± 1.37
Observation Period Week 52-1.1 ± 1.68
SecondaryChange From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Estradiol

Serum hormones levels were tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum estradiol.

Time frame:
From Week 0 up to Treatment Period Week 26 and Observation Period Week 52
Reported as:
Mean · Picomoles Per Litre (pmol/L)
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Estradiol
Picomoles Per Litre (pmol/L)Atrasentan
Treatment Period Week 13-11.7 ± 44.57
Treatment Period Week 26-18.6 ± 42.04
Observation Period Week 13-17.8 ± 62.78
Observation Period Week 26-47.3 ± 39.97
Observation Period Week 3920.3 ± 4.78
Observation Period Week 5210.5 ± 45.54
SecondaryChange From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Lutenizing Hormone (LH)

Serum hormones levels will be tested during the Treatment and Observational Periods. A positive change from baseline indicated an increase in serum lutenizing hormone.

Time frame:
From Week 0 to up to Treatment Period Week 26 and Observation Period Week 52
Reported as:
Mean · International Units/Liter (IU/L)
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Lutenizing Hormone (LH)
International Units/Liter (IU/L)Atrasentan
Treatment Period Week 131.0 ± 2.60
Treatment Period Week 260.7 ± 2.44
Observation Period Week 131.3 ± 1.33
Observation Period Week 261.9 ± 2.35
Observation Period Week 390.5 ± 0.07
Observation Period Week 521.8 ± 3.46
SecondaryChange From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in in Follicle Stimulating Hormone (FSH)

Serum hormones levels will be tested during the Treatment and Observational Periods. A positive change from baseline indicated an increase in serum follicle stimulating hormone.

Time frame:
From Week 0 to Treatment Week 26 and Observation Week 52
Reported as:
Mean · International Units/Liter (IU/L)
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in in Follicle Stimulating Hormone (FSH)
International Units/Liter (IU/L)Atrasentan
Treatment Period Week 131.1 ± 2.43
Treatment Period Week 260.8 ± 1.91
Observation Period Week 130.4 ± 1.60
Observation Period Week 260.7 ± 1.49
Observation Period Week 390.4 ± 1.57
Observation Period Week 520.8 ± 0.59
SecondaryChange From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Inhibin B

Serum hormones levels will be tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum Inhibin B.

Time frame:
From Week 0 up to Treatment Period Week 26 and Observation Period Week 52
Reported as:
Mean · picogram per milliliter (pg/mL)
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Inhibin B
picogram per milliliter (pg/mL)Atrasentan
Treatment Period Week 13-2.7 ± 24.19
Treatment Period Week 26-8.8 ± 34.73
Observation Period Week 13-7.2 ± 20.77
Observation Period Week 26-22.7 ± 27.10
Observation Period Week 39-21.0 ± 16.97
Observation Period Week 52-5.5 ± 2.12

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to approximately 30 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atrasentan0/20 (0%)3/20 (15%)12/20 (60%)
Most frequent serious events
Most frequent serious events
EventAtrasentan
DIABETIC KETOACIDOSISMetabolism and nutrition disorders2/20
CARDIOGENIC SHOCKCardiac disorders1/20
OSTEOMYELITISInfections and infestations1/20
POSTOPERATIVE RESPIRATORY FAILUREInjury, poisoning and procedural complications1/20
RESPIRATORY DISTRESSRespiratory, thoracic and mediastinal disorders1/20
RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders1/20
AORTIC DISSECTIONVascular disorders1/20
Most frequent other events
Showing 10 of 51
Most frequent other events
EventAtrasentan
OEDEMA PERIPHERALGeneral disorders4/20
NASOPHARYNGITISInfections and infestations4/20
DIARRHOEAGastrointestinal disorders2/20
NON-CARDIAC CHEST PAINGeneral disorders2/20
HEADACHENervous system disorders2/20
DYSPNOEARespiratory, thoracic and mediastinal disorders2/20
ANAEMIABlood and lymphatic system disorders1/20
HAEMORRHAGIC ANAEMIABlood and lymphatic system disorders1/20
ANGINA PECTORISCardiac disorders1/20
LEFT VENTRICULAR HYPERTROPHYCardiac disorders1/20

Baseline characteristics

Safety Analysis Set

Age, Continuous
Age, Continuous(years)Atrasentan
Mean55.1 ± 12.94
Sex: Female, Male
Sex: Female, Male(Participants)Atrasentan
Female0
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Atrasentan
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Atrasentan
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White15
More than one race0
Unknown or Not Reported0
08

Study locations

13 sites
  • Alliance Research Centers /ID# 125945
    Laguna Hills, California 92653-3621, United States
  • Frank Clark Urology Center /ID# 147794
    Santa Monica, California 90404, United States
  • Research by Design, LLC /ID# 160784
    Evergreen Park, Illinois 60805, United States
  • Southern IL Univ School of Med /ID# 129010
    Springfield, Illinois 62702, United States
  • Crescent City Clinical Res Ctr /ID# 150989
    Metairie, Louisiana 70006, United States
  • Tulane Univ /ID# 130308
    New Orleans, Louisiana 70112, United States
  • Albany Medical College /ID# 131068
    Albany, New York 12208, United States
  • Urologic Consultants of Southeastern Pennsylvania /ID# 124277
    Bala-Cynwyd, Pennsylvania 19004-1017, United States
  • Eastern Virginia Med School /ID# 153740
    Norfolk, Virginia 23507-1627, United States
  • Charite Research Organisation GmbH /ID# 154264
    Berlin, 10117, Germany
  • Ospedale S. Carlo Borromeo /ID# 151672
    Milan, 20153, Italy
  • SCDU Nefrologia e dialisi-CMID /ID# 151673
    Torino, 10154, Italy
  • Hospital Universitario Reina S /ID# 151692
    Cordoba, 14004, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Apr 2018, 36 months.

Results were first posted in May 2019, 1 year after primary completion.

Of 41 phase 2 interventional studies under Kidney Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2014
First posted
Apr 21, 2014
StartActual
Apr 6, 2015
Primary completionActual
Apr 18, 2018
CompletionActual
Jul 16, 2018
Results first posted
May 7, 2019
Last update
May 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02118714
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 21, 2014
Start date
Apr 6, 2015
Primary completion
Apr 18, 2018
Completion
Jul 16, 2018
Results posted
May 7, 2019
Last update
May 7, 2019

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atrasentan

Start the discussion